Cardiol Therapeutics Inc. (CRDL) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-85.6%

$0.15

vs $1.04 price

Levered DCF

$0.17

After debt service

Piotroski score

2 / 9

Weak

Altman Z-score

5.62

Safe zone

Rating

Overall 2 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
P/E	-3.36×	-3.61×	-2.54×	-1.41×	-3.2×	-4.03×	-8.66×	-7.74×
P/B	6.37×	5.33×	2.55×	1.12×	1.33×	6.26×	8.08×	5.55×
P/S	0×	0×	0×	0×	1,623.27×	0×	0×	0×
EV / EBITDA	-2.75×	-2.79×	-1.77×	0.03×	-0.7×	-4.33×	-10.74×	-14.67×
Gross margin	0.0%	0.0%	0.0%	0.0%	-179.9%	0.0%	0.0%	0.0%
Operating margin	0.0%	0.0%	0.0%	0.0%	-49092.4%	0.0%	0.0%	0.0%
Net margin	0.0%	0.0%	0.0%	0.0%	-40170.9%	0.0%	0.0%	0.0%
Current ratio	4.16×	4.52×	4.36×	6.27×	7.53×	5.94×	20.81×	11.22×
Debt / equity	0.01×	0.01×	0.01×	0×	0×	0.01×	0.01×	0.01×
Interest coverage	0×	0×	0×	0×	0×	0×	-17,543.88×	-11.14×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Return on equity	-189.2%	-148.3%	-75.1%	-59.3%	-32.8%	-122.1%	-71.9%	-71.4%
Return on invested capital	-190.6%	-161.8%	-79.1%	-79.1%	-40.0%	-121.0%	-73.3%	-32.8%
Return on assets	-143.2%	-115.1%	-57.8%	-49.9%	-28.5%	-101.9%	-68.1%	-64.4%
Free cash flow yield	-21.0%	-19.0%	-35.1%	-63.2%	-23.3%	-11.0%	-10.0%	-8.8%
Earnings yield	-29.7%	-27.8%	-29.5%	-52.9%	-24.7%	-19.5%	-8.9%	-12.9%
Enterprise value	$92.6M	$101.3M	$37.2M	-$603.9K	$17.3M	$69.2M	$111.7M	$107.1M
Net debt / EBITDA	0.63×	0.84×	1.66×	1.94×	3.38×	0.87×	0.65×	2.26×
Cash conversion cycle (days)	0	0	-14,852	-13,858	-8,289	-2,863	17,734	17,386